Bioquell plc announced that at its annual meeting held on May 28, 2009, Nigel Keen replaced John Salkeld, who is retiring from the board, as chairman of the company.

Bioquell plc reported consolidated earnings results for the year ended December 31, 2008. For the year, the company reported revenues were £34.4 million compared to revenue of £34.1 million for the previous year. Profit before tax was £5.00 million, increased 20%, compared to pre tax profit of £4.17 million for the previous year. Profit was £3.72 million or 8.3 pence per diluted share compared to profit of £3.65 million or 8.2 pence per diluted share for the previous year. For the year, the company reported operating profit of £5.2 million compared to the £4.2 million for the previous year. For the year, the company reported net cash used in operating activities of £5.8 million compared to the £2.39 million for the previous year. The Board is recommending the payment of a final dividend of 2.2 pence per ordinary share, which represents a 10% increase on the prior year. The final dividend will be payable on July 3, 2009 to shareholders on the register on June 12, 2009. The company reported that after 18 years on the Board, John Salkeld retires as Chairman of the company at the annual general meeting to be held on May 28, 2009. Nigel Keen, currently a non-executive director, is to succeed Mr. Salkeld as Chairman. Tony Bourne, who is currently Chief Executive of the British Medical Association, joined the Board as a non-executive director.

Bioquell plc, Annual General Meeting, May 28, 2009 Agenda: To approve statutory accounts for the year ended December 31, 2008.